$CDXS
CODEXIS, INC.

2024 Q3 Form 10-Q Financial Statement

#000120037524000022 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $12.83M $7.979M
YoY Change 38.33% -62.58%
Cost Of Revenue $4.317M $3.462M
YoY Change 91.95% 8.94%
Gross Profit $8.516M $4.517M
YoY Change 21.17% -75.11%
Gross Profit Margin 66.36% 56.61%
Selling, General & Admin $13.57M $15.67M
YoY Change 10.29% 17.25%
% of Gross Profit 159.32% 346.93%
Research & Development $11.51M $11.41M
YoY Change -15.79% -34.16%
% of Gross Profit 135.1% 252.67%
Depreciation & Amortization $1.184M $1.239M
YoY Change -12.75% -16.28%
% of Gross Profit 13.9% 27.43%
Operating Expenses $25.07M $27.08M
YoY Change -3.43% -11.78%
Operating Profit -$16.56M -$22.73M
YoY Change -48.36% 80.04%
Interest Expense $849.0K $972.0K
YoY Change -19.91% -13.29%
% of Operating Profit
Other Income/Expense, Net -$4.922M -$985.0K
YoY Change 26.37% 10844.44%
Pretax Income -$20.63M -$22.75M
YoY Change -40.89% 97.54%
Income Tax $10.00K $10.00K
% Of Pretax Income
Net Earnings -$20.64M -$22.76M
YoY Change -40.87% 97.47%
Net Earnings / Revenue -160.84% -285.19%
Basic Earnings Per Share -$0.29 -$0.32
Diluted Earnings Per Share -$0.29 -$0.32
COMMON SHARES
Basic Shares Outstanding 70.93M shares 70.56M shares
Diluted Shares Outstanding 72.03M shares 70.38M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $90.26M $73.20M
YoY Change 20.99% -20.52%
Cash & Equivalents $37.45M $18.60M
Short-Term Investments $52.80M $54.60M
Other Short-Term Assets $300.0K $900.0K
YoY Change -95.71% -79.01%
Inventory $2.103M $2.232M
Prepaid Expenses $3.200M $2.100M
Receivables $16.54M $12.39M
Other Receivables $0.00 $0.00
Total Short-Term Assets $112.9M $91.40M
YoY Change 9.6% -23.86%
LONG-TERM ASSETS
Property, Plant & Equipment $13.27M $13.97M
YoY Change -13.19% -40.12%
Goodwill $2.463M $2.463M
YoY Change 0.0% -23.03%
Intangibles
YoY Change
Long-Term Investments $5.790M $9.700M
YoY Change -67.83% -54.63%
Other Assets $1.928M $1.841M
YoY Change 165.56% 269.68%
Total Long-Term Assets $35.28M $40.61M
YoY Change -31.41% -53.17%
TOTAL ASSETS
Total Short-Term Assets $112.9M $91.40M
Total Long-Term Assets $35.28M $40.61M
Total Assets $148.2M $132.0M
YoY Change -4.06% -36.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.212M $3.685M
YoY Change 35.96% -8.83%
Accrued Expenses $6.505M $5.417M
YoY Change -26.05% -22.63%
Deferred Revenue $10.01M $9.800M
YoY Change 8.39% -6.92%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $35.13M $30.54M
YoY Change -8.55% -14.54%
LONG-TERM LIABILITIES
Long-Term Debt $28.63M $28.37M
YoY Change
Other Long-Term Liabilities $1.279M $1.264M
YoY Change 4.92% -10.04%
Total Long-Term Liabilities $29.91M $29.63M
YoY Change 2353.65% 2008.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $35.13M $30.54M
Total Long-Term Liabilities $29.91M $29.63M
Total Liabilities $74.78M $70.56M
YoY Change 18.8% -14.61%
SHAREHOLDERS EQUITY
Retained Earnings -$552.4M -$531.8M
YoY Change 12.66% 16.77%
Common Stock $8.000K $7.000K
YoY Change 33.33% 16.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $73.40M $61.45M
YoY Change
Total Liabilities & Shareholders Equity $148.2M $132.0M
YoY Change -4.06% -36.16%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$20.64M -$22.76M
YoY Change -40.87% 97.47%
Depreciation, Depletion And Amortization $1.184M $1.239M
YoY Change -12.75% -16.28%
Cash From Operating Activities -$12.99M -$12.17M
YoY Change -20.34% -24.36%
INVESTING ACTIVITIES
Capital Expenditures $1.006M $395.0K
YoY Change 47.94% -75.02%
Acquisitions
YoY Change
Other Investing Activities $2.539M -$26.69M
YoY Change -704.52% -267020.0%
Cash From Investing Activities $1.533M -$27.09M
YoY Change -239.36% 1624.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.31M -197.0K
YoY Change -27650.91% -102.85%
NET CHANGE
Cash From Operating Activities -12.99M -12.17M
Cash From Investing Activities 1.533M -27.09M
Cash From Financing Activities 30.31M -197.0K
Net Change In Cash 18.85M -39.45M
YoY Change -207.68% 267.51%
FREE CASH FLOW
Cash From Operating Activities -$12.99M -$12.17M
Capital Expenditures $1.006M $395.0K
Free Cash Flow -$13.99M -$12.56M
YoY Change -17.6% -28.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67573000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67573000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70376000 shares
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6781000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
116026000 usd
CY2024Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P6M
CY2024Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2024Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2024Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2024Q1 us-gaap Investment Variable Interest Rate Type Extensible Enumeration
InvestmentVariableInterestRateTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#PrimeRateMember
CY2024Q1 us-gaap Investment Variable Interest Rate Type Extensible Enumeration
InvestmentVariableInterestRateTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#PrimeRateMember
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70376000 shares
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
260000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4682000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-22755000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
61447000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
126016000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
141000 usd
CY2023Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
331000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2716000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11523000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
86615000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
143000 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
859000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
260000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7853000 usd
us-gaap Net Income Loss
NetIncomeLoss
-34260000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-23000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
61447000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
144797000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
422000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
721000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7931000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5525000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
404000 usd
us-gaap Net Income Loss
NetIncomeLoss
-34140000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
124131000 usd
us-gaap Net Income Loss
NetIncomeLoss
-34140000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2946000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2517000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5525000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Other Noncash Income
OtherNoncashIncome
0 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
345000 usd
cdxs Amortization Of Discount On Short Term Investments
AmortizationOfDiscountOnShortTermInvestments
-487000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
14000 usd
us-gaap Increase Decrease In Finance Receivables
IncreaseDecreaseInFinanceReceivables
-7137000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-453000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2402000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2275000 usd
cdxs Increase Decrease In Employee Related Liabilities And Other Accrued Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilitiesAndOtherAccruedLiabilities
2598000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2022000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-761000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19957000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1525000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
15000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
57140000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
3000000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
750000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-55650000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4855000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
281000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
422000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
327000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8652000 usd
cdxs Costs Incurred In Connection With Equity Sales Agreements
CostsIncurredInConnectionWithEquitySalesAgreements
403000 usd
cdxs Costs Incurred In Connection With Equity Sales Agreements
CostsIncurredInConnectionWithEquitySalesAgreements
395000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
29521000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
642000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
404000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29084000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8275000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-46523000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21879000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66697000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20174000 usd
us-gaap Interest Paid Net
InterestPaidNet
890000 usd
us-gaap Interest Paid Net
InterestPaidNet
10000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
17000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
193000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
768000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
434000 usd
cdxs Transfer From Property And Equipment To Assets Held For Sale
TransferFromPropertyAndEquipmentToAssetsHeldForSale
59000 usd
cdxs Transfer From Property And Equipment To Assets Held For Sale
TransferFromPropertyAndEquipmentToAssetsHeldForSale
0 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18595000 usd
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1579000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20174000 usd
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
54600000 usd
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
73200000 usd
us-gaap Nature Of Operations
NatureOfOperations
Description of Business<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In these notes to the unaudited condensed consolidated financial statements, the “Company,” “Codexis,” “we,” “us,” and “our” refers to Codexis, Inc. and its subsidiaries on a consolidated basis.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins leveraging our proprietary CodeEvolver</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directed evolution technology platform.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously managed our business as two business segments, Performance Enzymes and Novel Biotherapeutics. During the third and fourth quarters of 2023, we made changes to the structure of our organization in connection with the restructuring of our business that we announced in July 2023, including the discontinuation of investment in certain development programs, primarily in our biotherapeutics business, consolidation of operations to our Redwood City, California headquarters, and headcount reduction. In connection with these organizational structure changes, corresponding changes were made to how our business is managed, how results are reported internally and how our Chief Executive Officer (“CEO”), our chief operating decision maker, assesses performance and allocates resources. As a result of these changes, our previous Performance Enzymes and Novel Biotherapeutics operating segments were combined into a single reportable segment. Effective October 1, 2023, the Company's operations are managed and reported to the CEO on a consolidated basis. The CEO assesses performance and allocates resources based on the consolidated results of operations. We believe that these changes better align internal resources to create a more efficient and effective organizational structure. Under this new organizational and reporting structure, we managed our business as one reportable segment as of December 31, 2023. Comparative prior period disclosures that reflected the previous two segments' information have been revised to conform to this change in our reportable segment.</span></div>
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, deferred revenue, inventories, valuation of equity investments, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements.</span></div>
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7979000 usd
CY2024Q2 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
3213000 usd
CY2024Q2 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
5545000 usd
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
10000000 usd
CY2024Q2 us-gaap Contract With Customer Asset Credit Loss Expense
ContractWithCustomerAssetCreditLossExpense
0 usd
us-gaap Contract With Customer Asset Credit Loss Expense
ContractWithCustomerAssetCreditLossExpense
0 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
7814000 usd
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
3140000 usd
cdxs Contractwith Customer Liability New Activities Performance Obligation Satisfied Revenue Recognition
ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition
23351000 usd
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
34305000 usd
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13317000 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9312000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13317000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9312000 shares
CY2024Q2 cdxs Non Marketable Debt Securities Without Readily Determinable Fair Value Annual Amount
NonMarketableDebtSecuritiesWithoutReadilyDeterminableFairValueAnnualAmount
0 usd
CY2023Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
9700000 usd
CY2024Q2 us-gaap Cash
Cash
6195000 usd
CY2024Q2 cdxs Cash Cash Equivalents And Short Term Investments Amortized Cost
CashCashEquivalentsAndShortTermInvestmentsAmortizedCost
73222000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
23000 usd
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
73199000 usd
CY2023Q4 us-gaap Cash
Cash
8742000 usd
CY2023Q4 us-gaap Cash
Cash
8742000 usd
CY2023Q4 cdxs Cash Cash Equivalents And Short Term Investments Amortized Cost
CashCashEquivalentsAndShortTermInvestmentsAmortizedCost
65116000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
65116000 usd
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
108000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
108000 usd
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
6000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
7000 usd
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2118000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2570000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
2232000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
2685000 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2100000 usd
CY2024Q2 us-gaap Assets Held For Sale Not Part Of Disposal Group
AssetsHeldForSaleNotPartOfDisposalGroup
100000 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
900000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4600000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
600000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
53787000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
54798000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
39821000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
39311000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13966000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15487000 usd
CY2024Q2 us-gaap Depreciation
Depreciation
1239000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
1480000 usd
us-gaap Depreciation
Depreciation
2491000 usd
us-gaap Depreciation
Depreciation
2946000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
2766000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
2330000 usd
CY2024Q2 us-gaap Purchase Obligation
PurchaseObligation
2252000 usd
CY2023Q4 us-gaap Purchase Obligation
PurchaseObligation
1402000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
399000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
1003000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5417000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4735000 usd
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
4682000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2716000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7853000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5525000 usd
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
4682000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2716000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7853000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5525000 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
75856 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
214284 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.97
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.97
cdxs Net Proceeds From Stock Options Exercised
NetProceedsFromStockOptionsExercised
100000 usd
cdxs Net Proceeds From Stock Options Exercised
NetProceedsFromStockOptionsExercised
400000 usd
CY2023Q1 cdxs Sale Of Stock Securities Registered Aggregate Amount
SaleOfStockSecuritiesRegisteredAggregateAmount
200000000 usd
CY2023Q2 cdxs Sale Of Stock Consideration Received On Transaction Gross
SaleOfStockConsiderationReceivedOnTransactionGross
7100000 usd
cdxs Sale Of Stock Consideration Received On Transaction Gross
SaleOfStockConsiderationReceivedOnTransactionGross
8700000 usd
CY2023Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
6800000 usd
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
7900000 usd
CY2023Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
300000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
700000 usd
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1033000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1830000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
2065000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
3660000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M24D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.066
us-gaap Operating Lease Payments
OperatingLeasePayments
2357000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
3775000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2369000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4868000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5014000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2533000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
760000 usd
CY2024Q2 cdxs Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
318000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15862000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1692000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
14170000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3979000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10191000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
14170000 usd
cdxs Class Of Warrant Or Right Fair Value
ClassOfWarrantOrRightFairValue
900000 usd
CY2024Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
30000000 usd
CY2024Q2 cdxs Debt Instrument Payment In Kind Interest
DebtInstrumentPaymentInKindInterest
180000 usd
CY2024Q2 cdxs Debt Instrument Amortized Exit Fee
DebtInstrumentAmortizedExitFee
52000 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1261000 usd
CY2024Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
605000 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
28365000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
13264000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
15917000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
2653000 usd
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
31834000 usd
CY2024Q2 cdxs Debt Instrument Amortized Exit Fee
DebtInstrumentAmortizedExitFee
52000 usd
CY2024Q2 cdxs Debt Instrument Uncapitalized Payment In Kind Interest
DebtInstrumentUncapitalizedPaymentInKindInterest
1655000 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1261000 usd
CY2024Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
605000 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
28365000 usd
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
cdxs-20240630_cal.xml Edgar Link unprocessable
0001200375-24-000022-index-headers.html Edgar Link pending
0001200375-24-000022-index.html Edgar Link pending
0001200375-24-000022.txt Edgar Link pending
0001200375-24-000022-xbrl.zip Edgar Link pending
cdxs-20240630.htm Edgar Link pending
cdxs-20240630.xsd Edgar Link pending
cdxs_20240630xex311.htm Edgar Link pending
cdxs_20240630xex312.htm Edgar Link pending
cdxs_20240630xex321.htm Edgar Link pending
codexis-ex101innovatusfirs.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
cdxs-20240630_def.xml Edgar Link unprocessable
cdxs-20240630_lab.xml Edgar Link unprocessable
cdxs-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cdxs-20240630_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending